TY - JOUR
T1 - Rectal Cancer, Version 2.2022
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Al-Hawary, Mahmoud M.
AU - Azad, Nilofer
AU - Chen, Yi Jen
AU - Ciombor, Kristen K.
AU - Cohen, Stacey
AU - Cooper, Harry S.
AU - Deming, Dustin
AU - Garrido-Laguna, Ignacio
AU - Grem, Jean L.
AU - Gunn, Andrew
AU - Hecht, J. Randolph
AU - Hoffe, Sarah
AU - Hubbard, Joleen
AU - Hunt, Steven
AU - Jeck, William
AU - Johung, Kimberly L.
AU - Kirilcuk, Natalie
AU - Krishnamurthi, Smitha
AU - Maratt, Jennifer K.
AU - Messersmith, Wells A.
AU - Meyerhardt, Jeffrey
AU - Miller, Eric D.
AU - Mulcahy, Mary F.
AU - Nurkin, Steven
AU - Overman, Michael J.
AU - Parikh, Aparna
AU - Patel, Hitendra
AU - Pedersen, Katrina
AU - Saltz, Leonard
AU - Schneider, Charles
AU - Shibata, David
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Stotsky-Himelfarb, Eden
AU - Tavakkoli, Anna
AU - Willett, Christopher G.
AU - Gregory, Kristina
AU - Gurski, Lisa
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network.
PY - 2022/10
Y1 - 2022/10
N2 - This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a “watch-and-wait” nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org, covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.
AB - This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a “watch-and-wait” nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org, covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.
UR - http://www.scopus.com/inward/record.url?scp=85139886827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139886827&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2022.0051
DO - 10.6004/jnccn.2022.0051
M3 - Article
C2 - 36240850
AN - SCOPUS:85139886827
SN - 1540-1405
VL - 20
SP - 1139
EP - 1167
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 10
ER -
